molecules of the month


DNA-PK-selective kinase inhibitor

oral efficacy in xenograft radiation models

undisclosed screening and optimization

Mol. Cancer Ther., Mar. 27, 2020

Merck KGaA, Darmstadt, DE

1 min read

M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: